# A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

> **NCT04173793** · PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 109 (actual)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** AK102
- **DRUG:** Placebo
- **DRUG:** Statins and/or Ezetimibe

## Key facts

- **NCT ID:** NCT04173793
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-18
- **Primary completion:** 2022-09-26
- **Final completion:** 2022-09-26
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2023-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04173793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04173793, "A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04173793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*